Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study

Abstract

This 24-week double-blind, randomized, multicenter, placebo-controlled, parallel-group study was performed in 632 drug-naïve patients with type 2 diabetes to assess efficacy and tolerability of vildagliptin (50 mg qd, 50 mg bid, or 100 mg qd). HbA1c decreased modestly in patients receiving placebo (Δ=-0.3±0.1%) and to a significantly greater extent in patients receiving vildagliptin 50 mg qd (Δ=-0.8±0 .1%), 50 mg bid (Δ=-0.8±0.1%), or 100 mg qd (Δ=-0.9±0.1%, p<0.01 for all groups vs. placebo) from an average baseline of 8.4%. In patients diagnosed ≥3 months before enrollment, HbA1c increased with placebo (Δ=+0.2±0.2%) and between-treatment differences (vildagliptin-placebo) were -0.8±0.2% (p<0.001), -0.7±0.2% (p=0.003), and -0.9±0.2% (p<0.001) with vildagliptin 50 mg qd, 50 mg bid, and 100 mg qd, respectively. There was no apparent dose-response in the overall population; however, in patients with high baseline HbA1c, there were greater reductions with either 100 mg dose regimen (Δ=-1.3±0.2% and -1.4±0.2%) compared to 50 mg qd (Δ=-0.8±0.1%). Body weight decreased modestly in all groups (by 0.3 to 1.8 kg). The incidence of adverse events was similar across all groups and ≤1.2% of patients in any treatment group reported mild hypoglycemia. In conclusion, vildagliptin monotherapy decreases HbA1c in drug-naïve patients without weight gain and is well tolerated with minimal hypoglycemia.

dipeptidyl peptidase-4 - HbA1c - GLP-1 - incretin hormones

References

• 1 Ahrén B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes.  J Clin Endocrinol Metab. 2004;  89 2078-2084
• 2 Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes.  J Clin Endocrinol Metab. 2005;  90 4888-4894
• 3 Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.  Diabetes Obes Metab. 2005;  7 692-698
• 4 Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.  Horm Metab Res. 2006;  38 423-428
• 5 Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.  Diabetes Care. 2004;  27 2874-2880
• 6 Hochberg Y, Tamhane AC. Multiple comparison procedures. New York: Wiley 1987
• 7 DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.  Metabolism. 1989;  38 387-395
• 8 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).  Diabetes Care. 2003;  26 881-885
• 9 Kelley DE, Dunning BE, Ligueros-Say-Lan M, Holst JL, Deacon CF, Foley JE. Four-week treatment with vildagliptin increases fasting plasma levels of intact incretin hormones both in patients with type1 (T1DM) and type 2 (T2DM) diabetes.  Diabetes. 2006;  55 ((Suppl 1)) A344-A345
• 10 Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Foley JE, DeFronzo RA. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients.  J Clin Endocrinol Metab.. 2007 Jan 23;  , [Epub ahead of print]
• 11 He Y-L, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, Ligueros-Saylan M, Foley JE. Pharmacodynamics of vildagliptin in patients with type 2 diabetes.  J Clin Pharmacol.. 2007;  , (in press)

1 The trial (NCT 00099905) described here is registered with ClinicalTrials.gov.

Correspondence